Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | CCR5 | P51681 | 8/20 | 0.38 |
| ▸ | CCR4 | P51679 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4610033 | 0.85 | CCR5 (0.43) | CCR5CCR4KCNH2HDAC1HDAC6 | |
| SCHEMBL4607778 | 0.85 | DRD2 (0.44) | DRD2CCR5CCR4KCNH2HTR6 | |
| SCHEMBL5573793 | 0.82 | SMN1; SMN2 (0.44) | CCR5CCR4KCNH2HDAC1HDAC6 | |
| SCHEMBL4609485 | 0.80 | SLC6A2 (0.40) | DRD2CCR5CCR4KCNH2MDM2 | |
| SCHEMBL14571188 | 0.78 | ALDH1A1 (0.40) | DRD2CCR5HTR6MDM2PIK3C3 | |
| SCHEMBL4652432 | 0.78 | CCR5 (0.52) | CCR5CCR4KCNH2HTR6PIK3C3 | |
| SCHEMBL4652438 | 0.78 | CCR5 (0.52) | CCR5CCR4KCNH2HTR6PIK3C3 | |
| SCHEMBL4610004 | 0.76 | CCR5 (0.50) | CCR5CCR4KCNH2 | |
| SCHEMBL4609996 | 0.76 | CCR5 (0.50) | CCR5CCR4KCNH2 | |
| SCHEMBL4598546 | 0.76 | ALDH1A1 (0.41) | DRD2CCR5HTR6MDM2PIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | CCR5, CCR4, CCR1 | DRD2 1758/4885CCR5 1/4885CCR4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.